Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its Phase I clinical study of SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) developed in-house. The study, which focused on safety, efficacy, and pharmacokinetics, involved tumor patients undergoing chemotherapy.
In the Phase I trial, nine chemotherapy-treated tumor patients received a single subcutaneous injection of SCB-219M. Results showed that their platelet counts maintained or recovered to above 75 x 10^9/L, the threshold for chemotherapy-induced thrombocytopenia (CIT), within one week. This effect persisted for at least three weeks, covering the duration of the chemotherapy cycle. In contrast, platelet levels in a control group of similar patients who only received chemotherapy fell below 75 x 10^9/L within one to three weeks.
The clinical data thus far indicates that SCB-219M is well-tolerated and safe, with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported.- Flcube.com
